Omnicell (OMCL)
(Delayed Data from NSDQ)
$26.57 USD
-0.19 (-0.71%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $26.59 +0.02 (0.08%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.57 USD
-0.19 (-0.71%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $26.59 +0.02 (0.08%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth B Momentum C VGM
Zacks News
Omnicell (OMCL) Banks on Product Launches, Global Growth
by Zacks Equity Research
Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
by Zacks Equity Research
Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
by Zacks Equity Research
Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OMCL vs. PRVA: Which Stock Is the Better Value Option?
Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is Omnicell (OMCL) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.